Laboratorios Richmond SACIF

Laboratorios Richmond SACIF Equity

The The Equity of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is 64.30 B ARS. In the previous year, The Equity was 22.55 B ARS — a change of 185.14% (higher).

Equity

64.30 BARS

YoY

185.14%

Last updated:

In 2024, Laboratorios Richmond SACIF's equity was 64.30 B ARS, a 185.14% increase from the 22.55 B ARS equity in the previous year.

The Laboratorios Richmond SACIF Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
1.25 B ARS
Jan 1, 2018
1.62 B ARS
Jan 1, 2019
2.79 B ARS
Jan 1, 2020
5.10 B ARS
Jan 1, 2021
10.31 B ARS
Jan 1, 2022
10.09 B ARS
Jan 1, 2023
22.55 B ARS
Jan 1, 2024
64.30 B ARS
The Laboratorios Richmond SACIF Equity history
YEAREquityYoY
64.30 BARS+185.14%
22.55 BARS+123.48%
10.09 BARS-2.15%
10.31 BARS+102.09%
5.10 BARS+82.81%
2.79 BARS+72.59%
1.62 BARS+29.04%
1.25 BARS+561.49%
189.46 MARS+97.15%
96.10 MARS+3.33%
93.00 MARS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Laboratorios Richmond SACIF's Equity

Laboratorios Richmond SACIF's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Laboratorios Richmond SACIF's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Laboratorios Richmond SACIF's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Laboratorios Richmond SACIF's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Laboratorios Richmond SACIF’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

The Equity of Laboratorios Richmond SACIF is 64.30 B ARS in 2024.

The Equity of Laboratorios Richmond SACIF changed from 22.55 B ARS to 64.30 B ARS, representing a 185.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

The Equity's ARS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Laboratorios Richmond SACIF historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF